Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Privately-held biotech firm MacroGenics has signed an agreement with Gilead Sciences (NASDAQ: GILD ) to develop and produce Dual-Affinity Re-Targeting (DART) next-generation antibody therapeutics, according to a press release on MacroGenics's site.
MacroGenics's deal with Gilead could be worth up to more than $1.1 billion in payouts for the company if the DART program hits on all four of its milestones. MacroGenics may also receive royalties on any future sales that the program produces.
Gilead's Senior Vice President of Oncology and Inflammation Therapeutics, Dr. Roy D. Baynes, explained Gilead's aim in the deal, saying:
This partnership underscores Gilead's commitment to developing innovative therapies that address significant unmet medical needs for patients with cancer and other life-threatening diseases.
Shares of Gilead rose more than 1.5% on Monday.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.